This application constitutes a renewal for a Center for AIDS Research (CFAR) grant, for the CFAR established at UCLA in September, 1991. Although this application constitutes a renewal, our current CFAR is funded for a total of only three years, compared to the other CFARs, which were funded for five years. At the time of submission of this application, we have been in operation for only two years. The overall research theme of the UCLA CFAR is promotion of research into HIV-1 pathogenesis and immune function and dysfunctions in AIDS and HIV infection. This CFAR is specifically designed to promote and facilitate basic science research efforts and to catalyze new areas of investigation at the basic and clinical science level. The Director is Dr. Irvin S.Y. Chen, nd the Co-Director is Dr. Ronald Mitsuyasu. This CFAR consist of the Administrative Core; the Developmental Core; three laboratory cores, """"""""Virology/BSL3 Tissue Culture"""""""", """"""""Flow Cytometry/Cell Sorting"""""""" and """"""""SCID Mouse/Human Chimera""""""""; and two clinical cores, """"""""Clinical/Basic Sciences Interface"""""""" and """"""""Gene and Cellular Therapy""""""""; as well as internal and external advisory committees. We are focused on two major research strengths at UCLA which complement a strong clinical trials unit under the direction of the CFAR Co-Director, Dr. Ronald Mitsuyasu. These two research strengths are: 1) investigations into viral pathogenesis; and 2) immune function and restoration, including cytokine research and gene therapy. We envision that this CFAR will provide a structure for innovation, leading to greater understanding of HIV-1 pathogenesis and immune function through interdisciplinary interactions and collaborations. In time, these advances and research will lead to novel therapeutic approaches. The overall goals of the CFAR are to: 1. Promote innovative ideas about new therapeutic approaches through an understanding of basic pathogenic and immunologic aspects of HIV-1 disease. 2. Promote multidisciplinary research approaches involving virology, immunology, animal models and basic studies of HIV pathogenesis. 3. Promote interdisciplinary basic/clinical science approaches to AIDS research, with a particular emphasis on facilitating development of basic science advances toward novel diagnostic, therapeutic and preventative approaches to HIV disease (""""""""transnational"""""""" research). The Funded Research Base for this CFAR consists of 17 NIAID-funded projects, totalling $6,531,384. In total, there are 43 CFAR investigators, both NIAID and non-NIAID, who may use CFAR resources,l demonstrating the breadth of AIDS research activities to be supported by the UCLA CFAR.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI028697-05
Application #
2064570
Study Section
Special Emphasis Panel (SRC (71))
Project Start
1991-09-01
Project End
1999-06-30
Budget Start
1995-07-01
Budget End
1996-06-30
Support Year
5
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Swendeman, Dallas; Fehrenbacher, Anne E; Roy, Soma et al. (2018) Gender disparities in depression severity and coping among people living with HIV/AIDS in Kolkata, India. PLoS One 13:e0207055
Beymer, Matthew R; Kofron, Ryan M; Tseng, Chi-Hong et al. (2018) Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County. Int J STD AIDS 29:557-562
Matassoli, Flávio Lemos; Leão, Ihid Carneiro; Bezerra, Bruno Braz et al. (2018) Hydroxypropyl-Beta-Cyclodextrin Reduces Inflammatory Signaling from Monocytes: Possible Implications for Suppression of HIV Chronic Immune Activation. mSphere 3:
Ramos, Juan C; Sparano, Joseph A; Rudek, Michelle A et al. (2018) Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). Clin Lymphoma Myeloma Leuk 18:180-190.e2
Jia, Qingmei; Bowen, Richard; Dillon, Barbara Jane et al. (2018) Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. Sci Rep 8:7009
Woo, Jin Seok; Srikanth, Sonal; Kim, Kyun-Do et al. (2018) CRACR2A-Mediated TCR Signaling Promotes Local Effector Th1 and Th17 Responses. J Immunol 201:1174-1185
Van, Christina; Condro, Michael C; Lov, Kenny et al. (2018) PACAP/PAC1 Regulation of Inflammation via Catecholaminergic Neurons in a Model of Multiple Sclerosis. J Mol Neurosci :
Arfer, Kodi B; Tomlinson, Mark; Mayekiso, Andile et al. (2018) Criterion validity of self-reports of alcohol, cannabis, and methamphetamine use among young men in Cape Town, South Africa. Int J Ment Health Addict 16:45-52
Furler, Robert L; Nixon, Douglas F; Brantner, Christine A et al. (2018) TGF-? Sustains Tumor Progression through Biochemical and Mechanical Signal Transduction. Cancers (Basel) 10:
Shannon, Chelsea Lee; Bristow, Claire; Hoff, Nicole et al. (2018) Acceptability and Feasibility of Rapid Chlamydial, Gonococcal, and Trichomonal Screening and Treatment in Pregnant Women in 6 Low- to Middle-Income Countries. Sex Transm Dis 45:673-676

Showing the most recent 10 out of 942 publications